R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
Publication date
2022-09-02
Authors
Al-Sarayfi, Diana
Meeuwes, Frederik O.
Durmaz, Müjde
Issa, Djamila E.
Brouwer, Rolf E.
Beeker, Aart
van Rhenen, Anna
Mutsaers, Pim G.N.J.
Böhmer, Lara H.
van der Poel, Marjolein W.M.
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
cc_by
Abstract
Keywords
Anthracyclines/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/therapeutic use, Humans, Lymphoma, Large B-Cell, Diffuse/pathology, Prednisone/therapeutic use, Treatment Outcome, Vincristine/therapeutic use, Hematology, Oncology, Letter
Citation
Al-Sarayfi, D, Meeuwes, F O, Durmaz, M, Issa, D E, Brouwer, R E, Beeker, A, van Rhenen, A, Mutsaers, P G N J, Böhmer, L H, van der Poel, M W M, te Boome, L, van Meerten, T, Chamuleau, M E D, Zijlstra, J M, Brink, M & Nijland, M 2022, 'R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma', Blood cancer journal, vol. 12, no. 9, 125. https://doi.org/10.1038/s41408-022-00723-4